Afficher la couverture 'Drugging histone methyltransferases in cancer | Richart, Laia' en grand format
/5

0 avis

Drugging histone methyltransferases in cancer

Archive ouverte

Richart, Laia | Margueron, Raphaël

Edité par CCSD ; Elsevier -

International audience. Targeting chromatin-modifying enzymes is a promising strategy for cancer treatment. The antitumor effectivity of compounds inhibiting histone methyltransferases - mainly EZH2 - is currently being tested in phase I/II clinical trials, some of them showing positive results in hematological malignancies and solid tumors of specific mutational background. In this review, we aim at highlighting the recent advances in the field of histone methyltransferase inhibitors and describing the challenges that need to be addressed for their successful implementation in the clinics.

Suggestions

Du même auteur

Enhancer rewiring in tumors: an opportunity for therapeutic intervention

Archive ouverte | Richart, Laia | CCSD

International audience

EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition

Archive ouverte | Romero, Pierre | CCSD

International audience. Mutations in chromatin regulators are widespread in cancer. Among them, the histone H3 lysine 27 methyltransferase Polycomb Repressive Complex 2 (PRC2) shows distinct alterations according to...

XIST loss impairs mammary stem cell differentiation and increases tumorigenicity through Mediator hyperactivation

Archive ouverte | Richart, Laia | CCSD

International audience. X inactivation (XCI) is triggered by upregulation of XIST, which coats the chromosome in cis, promoting formation of a heterochromatic domain (Xi). XIST role beyond initiation of XCI is only ...

Chargement des enrichissements...